tiprankstipranks
TipRanksTop Financial ExpertsInsidersAnsbert Gadicke

Ansbert Gadicke Insider Profile

4 Followers
Ansbert Gadicke, Ten Percent Owner at Aktis Oncology, Inc., holds 10.26M shares in Aktis Oncology, Inc. (Ticker: AKTS), holds 4.78M shares in Werewolf Therapeutics (Ticker: HOWL), holds 3.45M shares in iTeos Therapeutics (Ticker: ITOS).
See the Hottest Stocks Based on Insider Trading >
tipranks
Ansbert Gadicke

Ansbert Gadicke
Aktis Oncology, Inc. (AKTS)
Ten Percent Owner

Ranked #22,405 out of 109,030 Corporate Insiders

Profitable Transactions

58%
7 out of 12 Profitable Transactions

Average Return

+6.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$463M
51.66%
35.12%
12.20%
1.02%
<0.01% Others
A breakdown of Ansbert Gadicke's holdings
See the Top Stocks by Insiders

Insider Roles

Aktis Oncology, Inc.
(AKTS)
Ten Percent Owner
Cullinan Management
(CGEM)
Director
Kalaris Therapeutics
(KLRS)
Director, Ten Percent Owner
Werewolf Therapeutics
(HOWL)
Former 10% Owner
+1 other positions
Roles that Ansbert Gadicke holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Repare Therapeutics
(RPTX)
Rating:Informative Sell
Date:Mar 15, 2021 - Mar 15, 2022
Return:+57.20%
The most profitable trade made by Ansbert Gadicke
See the Latest Stocks Traded by Insiders

Ansbert Gadicke's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
AKTS
Aktis Oncology, Inc.
Jan 14, 2026
Ten Percent Owner
Uninformative Buy
―
$239.06M
PETX
Aratana
Mar 10, 2014
―
Informative Sell
538.53K
$16.67M
CHMA
Chiasma
―
―
―
―
HARP
Harpoon Therapeutics
Jun 02, 2021
―
Uninformative Sell
1.19M
$145.61M
TCRR
TCR2 Therapeutics
Jun 05, 2023
―
Uninformative Sell
―
$0.00
RPTX
Repare Therapeutics
Jul 13, 2021
―
Uninformative Sell
2.08M
$10.29M
ITOS
iTeos Therapeutics
May 15, 2025
―
Informative Sell
8.32M
$35.05M
KLRS
Kalaris Therapeutics
Aug 01, 2022
Director, Ten Percent Owner
Uninformative Buy
15.00M
$56.46M
ONCR
Oncorus
Oct 08, 2020
―
Informative Buy
4.88M
$299.51K
CGEM
Cullinan Management
Sep 20, 2021
Director
Uninformative Sell
103.34K
$162.51M
HOWL
Werewolf Therapeutics
Dec 04, 2025
Former 10% Owner
Uninformative Sell
183.28K
$4.70M
~RSLS
ReShape Lifesciences
Feb 25, 2009
―
Informative Buy
2.03M
$10.69M
VSTM
Verastem
Feb 03, 2012
Director
Uninformative Buy
―
$27.38K
IDIX
Idenix Pharma
―
―
―
―
~RDUS
Radius Health
Sep 29, 2016
―
Uninformative Sell
―
$21.59M
List of latest transactions for each holding click on a transaction to see Ansbert Gadicke's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Ansbert Gadicke insider profile FAQ

What is the percentage of profitable transactions made by Ansbert Gadicke?
The percentage of profitable transactions made by Ansbert Gadicke is 58%.
    What is the average return per transaction made by Ansbert Gadicke?
    The average return per transaction made by Ansbert Gadicke is 6.30%.
      What stocks does Ansbert Gadicke hold?
      Ansbert Gadicke holds: AKTS, PETX, CHMA, HARP, TCRR, RPTX, ITOS, KLRS, ONCR, CGEM, HOWL, ~RSLS, VSTM, IDIX, ~RDUS stocks.
        What was Ansbert Gadicke’s latest transaction?
        Ansbert Gadicke latest transaction was an Uninformative Buy of ―.
          What was Ansbert Gadicke's most profitable transaction?
          Ansbert Gadicke’s most profitable transaction was an Informative Sell of RPTX stock on March 15, 2021. The return on the trade was 57.20%.
            What is Ansbert Gadicke's role in Aktis Oncology, Inc.?
            Ansbert Gadicke's role in Aktis Oncology, Inc. is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.